| 标题 |
A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton's Tyrosine Kinase (BTK) Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/Refractory B Cell Malignancies |
| 网址 | |
| DOI | |
| 其它 |
期刊:Blood 作者:Alexey Danilov; Michael T. Tees; Krish Patel; William G. Wierda; Manish Patel; et al 出版日期:2023-12-02 |
| 求助人 | |
| 下载 | 暂无链接,等待应助者上传 |
PDF的下载单位、IP信息已删除
(2025-6-4)